Long term strategic cooperation between Kangmei pharmaceutical and BGI

[China Pharmaceutical network enterprise news] on the evening of October 31, Kangmei pharmaceutical industry announced that the company signed a strategic cooperation agreement with BGI in Shenzhen on the same day, and the two sides established a long-term strategic partnership with each other, intending to build a joint research institute and the company, and carry out long-term in-depth cooperation in platform construction, basic research, technology research and development, talent training, etc According to the insiders, the cooperation between Kangmei pharmaceutical and BGI is the combination of "wisdom +" leading enterprises in the whole industry chain of traditional Chinese medicine and modern gene technology The application of gene detection technology in the field of traditional Chinese medicine is a breakthrough and innovation   According to the announcement, Kangmei pharmaceutical will give full play to the company's advantages in the construction and layout of the whole industrial chain of traditional Chinese medicine, carry out business cooperation in combination with Huada gene's scientific research and transformation practice in medicine, accelerate the research and construction in the fields of TCM product development, TCM gene detection, TCM efficacy evaluation, TCM standardization, TCM function mechanism and the material basis of TCM theory, and help Promote the development of traditional Chinese medicine industry Wang Jian, chairman of BGI, has high hopes for this cooperation "Kangmei Pharmaceutical Co., Ltd is a successful enterprise in building the whole industry chain platform of traditional Chinese medicine in China This cooperation will give full play to the application potential of gene research in traditional Chinese medicine and make great contribution to the development of medicine and related industries," he said Ma Xingtian, chairman and general manager of Kangmei pharmaceutical, said: "the two sides of this strategic cooperation have complementary advantages They can achieve deep integration in production, learning and research, and link the upstream and downstream, promote the transformation of scientific research results as soon as possible, promote the inheritance and development of traditional Chinese medicine industry, better serve the health of hundred families, and inject new vitality into the" healthy China "strategy." As a new exploration of the inheritance, innovation and development of traditional Chinese medicine, the industry has high expectations on the combination of traditional Chinese medicine and gene technology According to media reports, Sheng Sitong, the first president of the Chinese medicine gene branch of the Chinese Medicine Information Research Association, a platform for academic research, development and exchange of traditional Chinese medicine and gene science, said recently that he would integrate gene science and technology, theoretical knowledge into the research and development of traditional Chinese Medicine, carry out the integration and collection of medical resources, build the gene database and gene database of traditional Chinese medicine with the help of gene Sequencing technology to detect and identify precious Chinese herbal medicines, and clinical gene detection technology to improve the level of prevention and treatment of traditional Chinese medicine in the treatment of terminal diseases and disease diagnosis and treatment will be conducive to the promotion and development of Chinese medicine industry In fact, at present, there are many kinds of Chinese herbal medicines with "gene identity card" Chen Shilin, director of the Institute of traditional Chinese medicine of the Chinese Academy of traditional Chinese medicine, recently revealed through the media that they have carried out gene identification on more than 10000 kinds of medicinal plants, sequenced the whole genome of four or five kinds of medicinal materials, including ginseng, and made a "gene identity card" for Chinese herbal medicine, and checked the quality and quality of Chinese herbal medicine through technological innovation At the same time, the research of genomics will also be applied to the synthetic biology of traditional Chinese medicine, the development of new drugs and so on   Industry insiders said that gene detection technology can ensure the quality and authenticity of traditional Chinese medicine, contribute to the establishment of the traceability system of traditional Chinese medicine, and play a positive role in further standardization of traditional Chinese medicine and improving the evaluation of curative effect of traditional Chinese medicine Kangmei pharmaceutical industry plays an important role in the whole industry chain platform of traditional Chinese medicine, especially the advantages of traditional Chinese medicine planting, price index resources and the advantages of BGI in gene detection technology The deep combination of potential is of great significance to ensure sufficient efficacy of traditional Chinese medicine to help traditional Chinese medicine provide effective diagnosis and treatment services to the people It is understood that Shenzhen Huada gene Co., Ltd was founded in 2010 and listed on Shenzhen Stock Exchange in 2017 As a global genomics research and development organization, Huadaji is committed to applying cutting-edge scientific research achievements and biotechnology in the field of human health and other related fields, and promoting the industrialization of genetic technology achievements Kangmei Pharmaceutical Co., Ltd was founded in 1997 and listed on the Shanghai Stock Exchange in 2001 It is a large-scale listed enterprise of "wisdom +" large health industry and a national high-tech enterprise that has laid out the whole industry chain of traditional Chinese medicine through the Internet and comprehensively built the "big health + big platform + big data + big service" system of the whole industry chain of traditional Chinese medicine Ranking among the top 500 Chinese enterprises and the top 2000 global enterprises, it is a 50 component index stock of Shanghai Stock Exchange and a pharmaceutical enterprise with a market value of more than 100 billion in the domestic capital market (reporter Li Baojin) original title: Kangmei pharmaceutical and BGI boost the development of traditional Chinese medicine with gene technology